

Supplemental Material

Effectiveness of ixekizumab in Chinese patients with moderate-severe plaque psoriasis with special area involvement: Sub-analysis of a prospective, multi-center, observational real-world study

Original Article

Authors and affiliations

Ying Li^{1*}, Chengzhi Lv^{2*}, Dang Lin³, Bingjiang Lin⁴, Juan Tao⁵, Chunlei Zhang⁶, Xiaoyong Zhou⁷, Han Ma⁸, Yi Lu⁹, Rong Chen⁹, Jinnan Li⁹, Guanshen Dou⁹, Yunsheng Liang¹⁰, Yanhua Liang¹¹, Yuling Shi¹

1. Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, 200443, Shanghai, China
2. Department of Dermatology, Dalian Dermatoses Hospital, Dalian, Liaoning, China
3. Department of Dermatology, Longgang Central Hospital of Shenzhen, Shenzhen, Guangdong, China
4. Department of Dermatology, Ningbo First Hospital, Ningbo, Zhejiang, China
5. Department of Dermatology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (HUST), Wuhan, Hubei, China.
6. Department of Dermatology, Peking University Third Hospital, Beijing, China.
7. Department of Dermatology, Wuhan No. 1 Hospital, Wuhan, Hubei, China.
8. Department of Dermatology, Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai City, China.
9. Eli Lilly and Company, Shanghai, China
10. Department of Dermatology, Dermatology Hospital, Southern Medical University, 516006, Baiyun, Guangzhou, China.
11. Department of Dermatology, Cosmetology and Venereology, Shenzhen Hospital, Southern Medical University, 510086, Shenzhen, China.


*Li Ying and Lv Chengzhi contributed equal to this manuscript

Corresponding authors:

Shi Yuling, Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, 200443, Shanghai, China. shiyuling1973@tongji.edu.cn


Liang Yunsheng, Department of Dermatology, Dermatology Hospital, Southern Medical University, 516006, Baiyun, Guangzhou, China. yunshengliang@aliyun.com

Liang Yanhua, Department of Dermatology, Cosmetology and Venereology, Shenzhen Hospital, Southern Medical University, 510086, Shenzhen, China. liangdoctor@163.com




Supplemental Figure 1: Proportion of patients with versus without psoriasis involvement in special body area achieving at least a 50% improvement in PASI at week 2 (PASI 50) **(A)** or at least a 75% **(B)** or 90% **(C)** improvement (PASI 75 and PASI 90, respectively) at week 12.

There were no significant differences found between patients with and without psoriasis involvement across the different special body areas except for where indicated. PASI, Psoriasis Area and Severity Index; SD, standard deviation.



Supplemental Figure 2: Proportion of patients across with versus without psoriasis involvement in special body areas achieving a DLQI 0/1 at week 2 **(A)** and week 12 **(B)**.

There were no significant differences found between patients with and without psoriasis involvement across the different special body areas except for where indicated. DLQI, Dermatology Life Quality Index; SD, standard deviation.



Supplemental Figure 3: PASI score at baseline, week 2 and week 12 across patients with **(A)** versus without **(B)** psoriasis involvement in special body areas. *PASI*, *Psoriasis Area and Severity Index*; *SD*, *standard deviation*.